CliffBio
biologic

Ovidrel

choriogonadotropin alfa

Loss of exclusivityJuly 2015projected — 12-year biologic exclusivity estimate
CompanyEMD Serono →See this company's full patent-cliff portfolio

Drug detail

Brand nameOvidrel
Active ingredientchoriogonadotropin alfa
Strength250MCG/0.5ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJuly 2003
Marketing statusRx

More from EMD Serono

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Ovidrel patent cliff — loss of exclusivity July 2015 | CliffBio